AR080471A1 - Participacion de la via de androgenos/receptores de androgenos en la enfermedad de fabry - Google Patents
Participacion de la via de androgenos/receptores de androgenos en la enfermedad de fabryInfo
- Publication number
- AR080471A1 AR080471A1 ARP110100713A ARP110100713A AR080471A1 AR 080471 A1 AR080471 A1 AR 080471A1 AR P110100713 A ARP110100713 A AR P110100713A AR P110100713 A ARP110100713 A AR P110100713A AR 080471 A1 AR080471 A1 AR 080471A1
- Authority
- AR
- Argentina
- Prior art keywords
- androgen
- fabry
- disease
- pathway
- subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Abstract
Terapias para el tratamiento de la enfermedad de Fabry que comprenden usar moléculas relacionadas con la vía de androgenos/receptores de androgenos (AR) como biomarcadores y el uso de enfoques dirigidos a la vía de androgenos/AR. La participacion de una vía de androgenos/AR aberrante en la enfermedad de Fabry no se ha descrito con anterioridad. La presente describe, (i) el uso de enfoques dirigidos a la vía de androgenos/AR como tratamientos terapéuticos para la enfermedad de Fabry y (2) el uso de los niveles de moléculas relacionadas con la vía de androgenos/AR en fluidos corporales o tejidos como biomarcadores para evaluar el avance de la enfermedad y la eficacia de los tratamientos en pacientes con Fabry. Reivindicacion 1: Un método para diagnosticar a enfermedad de Fabry en un sujeto que comprende los pasos de: recolectar una muestra del sujeto sospechado de padecer la enfermedad de Fabry; comparar un nivel de una o más moléculas seleccionadas del grupo que consiste de un androgeno, un precursor de androgeno, un metabolito de androgeno, un molécula de la vía de receptores de androgenos (AR) y uno o más genes AR de interés y metabolitos relacionados, en la muestra del sujeto sospechado de padece la enfermedad de Fabry, con el de un sujeto normal que no padece la enfermedad de Fabry determinar sí el sujeto sufre de la enfermedad de Fabry en base a un cambio estadísticamente significativo en los niveles de dichas una o más moléculas en la muestras entre el sujeto sospechado de padecer la enfermedad de Fabry y el sujeto normal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31080210P | 2010-03-05 | 2010-03-05 | |
US13/038,293 US20110217288A1 (en) | 2010-03-05 | 2011-03-01 | Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080471A1 true AR080471A1 (es) | 2012-04-11 |
Family
ID=44531528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100713A AR080471A1 (es) | 2010-03-05 | 2011-03-04 | Participacion de la via de androgenos/receptores de androgenos en la enfermedad de fabry |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110217288A1 (es) |
EP (1) | EP2542687A1 (es) |
AR (1) | AR080471A1 (es) |
AU (1) | AU2011223706A1 (es) |
CA (1) | CA2791994A1 (es) |
TW (1) | TW201138777A (es) |
WO (1) | WO2011109448A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
HUE043959T2 (hu) * | 2013-12-23 | 2019-09-30 | Bcn Peptides Sa | Bikalutamid analógok vagy (S)-bikalutamid, mint exocitózist aktiváló vegyületek lizoszomális tárolási zavar vagy glikogenózis kezelésében történõ alkalmazásra |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2136969C (en) * | 1992-06-12 | 2009-03-24 | Michael E. Lewis | Prevention and treatment of peripheral neuropathy |
WO2003086386A1 (en) * | 2002-04-09 | 2003-10-23 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
US20060269950A1 (en) * | 2005-05-19 | 2006-11-30 | Wyeth | Method of identifying compounds that modulate interaction of androgen receptor with beta-catenin |
EP2787345B8 (en) * | 2006-05-16 | 2016-04-13 | Amicus Therapeutics, Inc. | Treatment options for fabry disease |
WO2008011072A2 (en) * | 2006-07-19 | 2008-01-24 | Osurf (Ohio State University Research Foundation) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
MX2009009936A (es) * | 2007-03-20 | 2010-02-11 | Curis Inc | Amino piridina fusionada como inhibidores de hsp90. |
US8956825B2 (en) * | 2007-05-24 | 2015-02-17 | The United States Of America As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
US20090282496A1 (en) * | 2008-04-04 | 2009-11-12 | University Of Rochester Medical Center | Androgen Receptor Related Methods for Treating Bladder Cancer |
US8541487B2 (en) * | 2008-08-04 | 2013-09-24 | Ranee Spradlin | Materials, methods and compositions for a composite building material |
MX2011010565A (es) * | 2009-04-09 | 2011-10-19 | Baylor Res Inst | Uso de tetrahidrobiopterina como marcador y agente terapeutico para enfermedad de fabry. |
-
2011
- 2011-03-01 CA CA2791994A patent/CA2791994A1/en not_active Abandoned
- 2011-03-01 EP EP11751240A patent/EP2542687A1/en not_active Withdrawn
- 2011-03-01 US US13/038,293 patent/US20110217288A1/en not_active Abandoned
- 2011-03-01 AU AU2011223706A patent/AU2011223706A1/en not_active Abandoned
- 2011-03-01 WO PCT/US2011/026761 patent/WO2011109448A1/en active Application Filing
- 2011-03-04 AR ARP110100713A patent/AR080471A1/es unknown
- 2011-03-04 TW TW100107432A patent/TW201138777A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2791994A1 (en) | 2011-09-09 |
TW201138777A (en) | 2011-11-16 |
EP2542687A1 (en) | 2013-01-09 |
AU2011223706A1 (en) | 2012-09-20 |
US20110217288A1 (en) | 2011-09-08 |
WO2011109448A1 (en) | 2011-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201400491A1 (ru) | Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения | |
HRP20130852T1 (en) | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component | |
AR050215A1 (es) | Metodo para diagnosticar enfermedades utilizando copeptina. | |
ES2656962T3 (es) | Métodos para evaluar la receptividad del endometrio de una paciente | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
ES2570632T3 (es) | Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal | |
AR084723A1 (es) | microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR | |
WO2006125143A3 (en) | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
BR112012031071A2 (pt) | 8-proteínas de ligação à il-1 | |
WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
ES2570627T3 (es) | Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal | |
ES2570631T3 (es) | Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal | |
CA2815892C (en) | Analytical methods and arrays for use in the same | |
WO2013071012A3 (en) | Personalized strategic cancer treatment | |
WO2010099137A3 (en) | In situ methods for monitoring the emt status of tumor cells in vivo | |
WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
WO2017027391A3 (en) | Genetic abnormalities in plasma cell dyscrasias | |
WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
WO2013066879A3 (en) | SOLUBLE UROKINASE RECEPTOR (suPAR) IN DIABETIC KIDNEY DISEASE | |
BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits | |
AR080471A1 (es) | Participacion de la via de androgenos/receptores de androgenos en la enfermedad de fabry | |
GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
ES2570609T3 (es) | Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |